Bioinspired and biomimetic cancer-cell-derived membrane nanovesicles for preclinical tumor-targeted nanotheranostics

被引:9
|
作者
Prasad, Rajendra [1 ,2 ]
Mendes, Barbara B. [3 ]
Gorain, Mahadeo [4 ]
Kundu, Gopal Chandra [4 ,5 ,6 ]
Gupta, Narendra [7 ]
Peng, Berney [8 ]
Win, Eaint Honey Aung [8 ]
Qing, He [1 ]
Conde, Joao [3 ]
机构
[1] Tufts Univ, Dept Mech Engn, Medford, MA 02155 USA
[2] Indian Inst Technol BHU, Sch Biochem Engn, Varanasi 221005, Uttar Pradesh, India
[3] Univ Nova Lisboa, NOVA Med Sch, ToxOmics, NMS FCM,Fac Ciencias Med, Lisbon, Portugal
[4] Natl Ctr Cell Sci, Pune 411007, India
[5] Inst Eminence, Sch Biotechnol, Bhubaneswar 751024, India
[6] Kalinga Inst Med Sci KIMS, Inst Eminence, KIIT, Bhubaneswar 751024, India
[7] Trident Diagnost Ctr, Trivenee 302015, India
[8] Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA
来源
CELL REPORTS PHYSICAL SCIENCE | 2023年 / 4卷 / 11期
基金
欧洲研究理事会;
关键词
NANOPARTICLES; STRATEGIES; DELIVERY;
D O I
10.1016/j.xcrp.2023.101648
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Bioinspired cell-membrane-camouflaged nanohybrids have been proposed to enhance tumor targeting by harnessing their immune escape and self-recognition abilities. In this study, we introduce cancer-cell-derived membrane nanovesicles (CCMVs) integrated with gold nanorods (AuVNRs) in addition to therapeutic and imaging cargos such as doxorubicin and indocyanine green. This approach enhances targeted tumor imaging and enables synergistic chemophototherapeutics for solid tumors. CCMVs demonstrate significant tumor penetration and retention, serving as nanotheranostics with accessible surface biomarkers, biomimicking properties, and homologous targeting abilities. By evading uptake by the mononuclear phagocytic system, CCMVs can diffuse into the deep tumor core, leading to precise tumor reduction while preserving the surrounding healthy tissues. Notably, intravenous administration of these theranostic agents ensures biocompatibility, as evidenced by a survival period of approximately two months (up to 63 days) without any observed side effects. Our findings underscore the diagnostic and therapeutic potential of this biomimetic nanotheranostics platform.
引用
收藏
页数:23
相关论文
共 50 条
  • [41] Cancer cell membrane-coated biomimetic platform for tumor targeted photodynamic therapy and hypoxia-amplified bioreductive therapy
    Li, Shi-Ying
    Cheng, Hong
    Qiu, Wen-Xiu
    Zhang, Lu
    Wan, Shuang-Shuang
    Zeng, Jing-Yue
    Zhang, Xian-Zheng
    BIOMATERIALS, 2017, 142 : 149 - 161
  • [42] Recent Advances in Cell Membrane-Derived Biomimetic Nanotechnology for Cancer Immunotherapy
    Raza, Faisal
    Zafar, Hajra
    Zhang, Shulei
    Kamal, Zul
    Su, Jing
    Yuan, Wei-En
    Qiu, Mingfeng
    ADVANCED HEALTHCARE MATERIALS, 2021, 10 (06)
  • [43] Biomimetic cell membrane-coated nanocarriers for targeted siRNA delivery in cancer therapy
    Huang, Xin
    Guo, Haoyu
    Wang, Lutong
    Zhang, Zhicai
    Zhang, Weiyue
    DRUG DISCOVERY TODAY, 2023, 28 (04) : 1 - 9
  • [44] Tumor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and cell migration
    Muralidharan, Ranganayaki
    Babu, Anish
    Basalingappa, Kanthesh
    Munshi, Anupama
    Ramesh, Rajagopal
    CANCER RESEARCH, 2014, 74 (19)
  • [45] Engineering cell membrane-camouflaged COF-based nanosatellite for enhanced tumor-targeted photothermal chemoimmunotherapy
    Lin, Dan
    Lv, Wenxin
    Qian, Min
    Jiang, Guangwei
    Lin, Xiaojun
    Gantulga, Darambazar
    Wang, Yi
    BIOMATERIALS, 2025, 314
  • [46] Monocyte cell membrane-derived nanoghosts for targeted cancer therapy
    Krishnamurthy, S.
    Gnanasammandhan, M. K.
    Xie, C.
    Huang, K.
    Cui, M. Y.
    Chan, J. M.
    NANOSCALE, 2016, 8 (13) : 6981 - 6985
  • [47] Unlocking the power of nanomedicine: Cell membrane-derived biomimetic cancer nanovaccines for cancer treatment
    Zhao, Guo
    Wang, Shuhang
    Nie, Guangjun
    Li, Ning
    MED, 2024, 5 (07): : 660 - 688
  • [48] The cell-line-derived subcutaneous tumor model in preclinical cancer research
    Stephen M. Stribbling
    Anderson J. Ryan
    Nature Protocols, 2022, 17 : 2108 - 2128
  • [49] Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC)
    Deneka, Alexander Y.
    Boumber, Yanis
    Beck, Tim
    Golemis, Erica A.
    CANCERS, 2019, 11 (09)
  • [50] The cell-line-derived subcutaneous tumor model in preclinical cancer research
    Stribbling, Stephen M.
    Ryan, Anderson J.
    NATURE PROTOCOLS, 2022, 17 (09) : 2108 - 2128